Myotonic Dystrophy 1 Clinical Trial
Official title:
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the clinical study site every 8 weeks for a total of 7 doses. The final dose will occur at Week 48, followed by a final assessment at Week 54. After completion of Week 54 assessments, eligible participants will have the option to enroll into an open label extension (OLE) study, pending regulatory approval. An Independent Data Monitoring Committee (IDMC) comprised of members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02880735 -
Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy
|
N/A | |
Recruiting |
NCT06378216 -
Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
|
||
Active, not recruiting |
NCT06089018 -
Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
|
||
Completed |
NCT05662150 -
Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1
|
N/A | |
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Completed |
NCT05027269 -
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04712422 -
Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
|
||
Recruiting |
NCT05006924 -
Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
|
||
Recruiting |
NCT04656210 -
Myotonic Dystrophy - Vascular and Cognition
|
||
Completed |
NCT04634682 -
Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1
|
N/A | |
Withdrawn |
NCT06270186 -
Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach
|
N/A | |
Recruiting |
NCT06300307 -
Study of ATX-01 in Participants With DM1
|
Phase 1/Phase 2 | |
Completed |
NCT02729597 -
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study
|
N/A | |
Recruiting |
NCT06138743 -
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
|
Phase 1 | |
Not yet recruiting |
NCT05532813 -
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
|
Phase 3 | |
Active, not recruiting |
NCT04886518 -
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1
|
Phase 2 | |
Completed |
NCT05036447 -
Myotonic Dystrophy Type 1 and Resistance Exercise
|
N/A | |
Recruiting |
NCT03424460 -
Venous Thromboembolism in Myotonic Dystrophy Type 1
|
N/A | |
Recruiting |
NCT05865483 -
Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
|
||
Completed |
NCT04001920 -
Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1
|
N/A |